Skip to content
Screener

Net Income at other companies

Pfizer logo
PfizerPFE
-$248M-109%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.53B-0.1%
Merck & Co. logo
Merck & Co.MRK
-$1.34B-130%
Incyte logo
IncyteINCY
$585.61M+44.6%
Gilead Sciences logo
Gilead SciencesGILD
-$10.5B-636%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$31.82M-51.5%

Other financials

Income statement

See full
Revenue$13.0B+5.7%
Gross profit$9.2B+3.9%
EPS (diluted)$1.62+153%

Balance sheet

See full
Cash & equivalents$8.7B-30.8%
Total debt$43.3B-12.3%
Total equity$22.3B+28.0%
Total assets$87.6B-7.4%

Cash flow

See full
Operating cash flow$3.4B-13.4%
CapEx$305.0M-15.5%
Free cash flow$3.1B-13.2%

Valuation

See full
Market cap$138.03B+42.4%
Enterprise value$172.63B+29.1%
P/E14.9×-4.6×
P/S2.8×+0.8×

Profitability

See full
Gross margin70.2%-0.1pp
Net margin18.9%+8.4pp
FCF margin23.3%-7.3pp

Returns & leverage

See full
Return on equity46.7%+17.8pp
Debt / equity1.9×-0.9×
Current ratio1.5×+0.3×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 11:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000014272-26-000020
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Earnings/(Loss) before income taxes4,0861,7737,3264,744
Income tax provision7704601,331969
Net earnings/(loss)3,3161,3135,9943,775
Noncontrolling interest(1)29
Net earnings/(loss) attributable to BMS$3,317$1,310$5,994$3,766
Earnings/(Loss) per common share:
Basic$1.62$0.64$2.94$1.85
Diluted1.620.642.931.85

Item 1. FINANCIAL STATEMENTS

FAQ

What is Bristol-Myers Squibb's net income?
Bristol-Myers Squibb (BMY) reported net income of $3.32B in Q2 2026.
How has Bristol-Myers Squibb's net income changed year-over-year?
Bristol-Myers Squibb's net income increased by 153.2% year-over-year, from $1.31B to $3.32B.
What is the long-term trend for Bristol-Myers Squibb's net income?
Over 4 years (2021 to 2025), Bristol-Myers Squibb's net income has grown at a 0.2% compound annual growth rate (CAGR), from $6.99B to $7.05B.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Bristol-Myers Squibb's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude